<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551014</url>
  </required_header>
  <id_info>
    <org_study_id>15766-2</org_study_id>
    <nct_id>NCT04551014</nct_id>
  </id_info>
  <brief_title>Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm</brief_title>
  <official_title>Randomized Controlled Trial Investigating Use of Submucosal Injection of EverLift in Rates of Complete Resection of Nonpedunculated Polyps 4-9mm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of the study is to evaluate impact of submucosal injection of EverLift in achieving&#xD;
      complete resection during polypectomy of polyps 4-9mm during colonoscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The details of the proposed study are as follows:&#xD;
&#xD;
        1. Experimental group: using EverLift submucosal injection for polyps 4-9mm of the colon&#xD;
&#xD;
        2. Control group: not using EverLift submucosal injection for polyps 4-9mm of the colon&#xD;
&#xD;
        3. Methods:&#xD;
&#xD;
             1. Colonoscopy will be performed in the same standard of care manner as if no study&#xD;
                was taking place.&#xD;
&#xD;
             2. If polyps 4-9mm are identified, the endoscopist is randomized to performing&#xD;
                polypectomy with or without submucosal injection of EverLift.&#xD;
&#xD;
             3. After removal of the polypectomy, two biopsies are performed at the margin of the&#xD;
                polypectomy site to identify residual lesion.&#xD;
&#xD;
             4. The polyp as well as well as the two biopsies are reviewed by a pathologist.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Actual">July 15, 2021</completion_date>
  <primary_completion_date type="Actual">July 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completeness of resection</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary outcome measured is comparison of completeness of resection between the with EverLift and without EverLift groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resection</measure>
    <time_frame>During the procedure</time_frame>
    <description>The time between the snare is introduced till the polyp is removed and retrieved will be compared between the with and without EverLift groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>We will compare the number of snare attempts needed to remove the tissue adequately to the endoscopist's judgment</measure>
    <time_frame>During the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>4 weeks</time_frame>
    <description>We will compare rates of complications including perforation and immediate post-polypectomy bleeding, early post-polypectomy bleed (within 24 hours) and delayed post polypectomy bleed (between 24 hours and 30 days). Early post-polypectomy bleed and delayed post-polypectomy bleed is evaluated based on emergency room (ER) visit, inpatient stay, transfusion needed, repeat colonoscopy required, surgical intervention required, and mortality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>Polyp of Colon</condition>
  <condition>Adenomatous Polyp of Colon</condition>
  <arm_group>
    <arm_group_label>With EverLift</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polypectomy performed for polyps 4-9mm with submucosal injection of EverLift.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without EverLift</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polypectomy performed for polyps 4-9mm without submucosal injection of EverLift.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Use of EverLift</intervention_name>
    <description>Use of EverLift for submucosal injection prior to polypectomy</description>
    <arm_group_label>With EverLift</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Without use of EverLift</intervention_name>
    <description>Without use of EverLift for submucosal injection prior to polypectomy</description>
    <arm_group_label>Without EverLift</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years or older&#xD;
&#xD;
          -  Polyps 4-9mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Polyposis syndromes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shai Friedland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Shai Friedland</investigator_full_name>
    <investigator_title>Professor in Gastroenterology &amp; Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Colonic Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

